Her-2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: A pilot study comparing FISH, CISH and immunocytochemistry | Zendy

Kusum Kapila | Zendy; Shafiqa Al-Awadhi | Zendy; Francis Im | Zendy

Open Access

Her-2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: A pilot study comparing FISH, CISH and immunocytochemistry

Author(s) -

Kusum Kapila,

Shafiqa Al-Awadhi,

Francis Im

Publication year - 2011

Publication title -

journal of cytology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.267

H-Index - 19

eISSN - 0974-5165

pISSN - 0970-9371

DOI - 10.4103/0970-9371.80731

Subject(s) - cish , chromogenic in situ hybridization , immunohistochemistry , medicine , pathology , breast carcinoma , breast cancer , fluorescence in situ hybridization , trastuzumab , fine needle aspiration , gene duplication , carcinoma , cancer , in situ hybridization , oncology , gene expression , biopsy , gene , biology , biochemistry , chromosome

Breast cancers with Her-2 neu gene amplification are recognized as important markers for aggressive disease and targets which respond to therapy with trastuzumab. Her-2 neu testing on histological sections is routinely performed to select patients who may benefit from anti- Her-2 neu therapy. Few reports are available which document Her-2 neu status on fine needle aspirates (FNA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research